SCHEMBL5842683

SCHEMBL5842683

Cc1cc(C(Cl)C(=O)c2ccccc2)c(C)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.42
HSP90AA1 P07900 2/20 0.42
ALDH1A1 P00352 7/20 0.40
MAPT P10636 5/20 0.40
GAA P10253 5/20 0.40
AGTR1 P30556 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR55 Q9Y2T6 2/20 0.40
RAB9A P51151 3/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
APAF1 O14727 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9278740 0.81 ATM (0.46) ATMHSP90AA1ALDH1A1MAPTGAA
SCHEMBL9273543 0.78 RAB9A (0.44) ATMHSP90AA1ALDH1A1SMN1; SMN2GPR55
SCHEMBL11749607 0.76 ALDH1A1 (0.50) ATMHSP90AA1ALDH1A1GAAGPR55
SCHEMBL8757588 0.72 KMT2A (0.41) ATMHSP90AA1ALDH1A1MAPTGAA
SCHEMBL11753784 0.70 POLB (0.57) ATMMAPTSMN1; SMN2RAB9AMAPK1
SCHEMBL11750001 0.68 CES2 (0.47) ATMHSP90AA1ALDH1A1GAAGPR55
SCHEMBL11751222 0.68 TDP1 (0.42) ATMHSP90AA1ALDH1A1GAAGPR55
SCHEMBL11751949 0.68 LMNA (0.55) ATMHSP90AA1ALDH1A1MAPTGAA
SCHEMBL11095327 0.68 LMNA (0.39) LMNATDP1MCL1MEN1KMT2A
SCHEMBL458300 0.68 TDP1 (0.61) ATMHSP90AA1ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074783-B2 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-07-11 US disclosed
EP-1549622-A1 SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS Elian Pharmaceuticals Inc. (US) 2005-07-06 EP disclosed
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-15 US disclosed
WO-2004033436-A1 SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS ELAN PHARMACEUTICALS INC (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists BDKRB1, BDKRB2, HRH2 ATM 3132/4885HSP90AA1 2658/4885ALDH1A1 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.